Related references
Note: Only part of the references are listed.Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
T. Powles
ANNALS OF ONCOLOGY (2021)
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
S. Aeppli et al.
ESMO OPEN (2021)
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
Michael R. Harrison et al.
CANCER (2021)
Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma
Brian Rini et al.
CLINICAL GENITOURINARY CANCER (2021)
Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis
Fahad Quhal et al.
CURRENT OPINION IN UROLOGY (2021)
A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma
Irbaz Bin Riaz et al.
EUROPEAN UROLOGY (2021)
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis
Keiichiro Mori et al.
CANCER TREATMENT REVIEWS (2021)
Nivolumab plus cabozantinib (N plus C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
Andrea B. Apolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
Fahad Quhal et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting
David H. Aggen et al.
CLINICAL CANCER RESEARCH (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma: a real-world US study
Jennifer P. Hall et al.
FUTURE ONCOLOGY (2020)
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2020)
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Robert J. Motzer et al.
NATURE MEDICINE (2020)
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
Matthew D. Tucker et al.
CANCERS (2020)
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Robert J. Motzer et al.
CANCER CELL (2020)
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Laurence Albiges et al.
ESMO OPEN (2020)
Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
Bernard Escudier
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors
Arpita Desai et al.
FUTURE ONCOLOGY (2019)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert Motzer et al.
LANCET ONCOLOGY (2019)
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib The SURTIME Randomized Clinical Trial
Axel Bex et al.
JAMA ONCOLOGY (2019)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Sunitinib Alone or after Nephrectomy in Renal Cancer
Chihiro N. Kondoh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Daniel Y. C. Heng et al.
LANCET ONCOLOGY (2013)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
RC Flanigan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
GHJ Mickisch et al.
LANCET (2001)
Share Paper
